News & Updates

A recent study has shown the safety and efficacy of AK 101 (ebdarokimab) in the treatment of patients with plaque psoriasis, achieving ≥75-percent improvement in Psoriasis Area and Severity Index (PASI 75) and Static Physicians Global Assessment (sPGA) 0/1 response.

The updated efficacy analysis of the phase III MARIPOSA trial continues to favour amivantamab plus lazertinib over osimertinib for first-line (1L) treatment of patients with EGFR-mutant (EGFRm) advanced non-small cell lung cancer (NSCLC).